Literature DB >> 23685950

Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells.

Ke Ma1, Li-min Yang, Hong-zhuan Chen, Yang Lu.   

Abstract

AIM: To investigate the actions of the muscarinic agonist carbachol on glutamate-induced neurotoxicity in PC12 cells, and the underlying mechanisms.
METHODS: PC12 cells were treated with different concentrations of glutamate for 24 or 48 h. The cell viability was measured using MTT assay, and the expression and activation of GSK-3β were detected with Western blot. β-Catenin translocation was detected using immunofluorescence. Luciferase reporter assay and real-time PCR were used to analyze the transcriptional activity of β-catenin.
RESULTS: Glutamate (1, 3, and 10 mmol/L) induced PC12 cell death in a dose-dependent manner. Moreover, treatment of the cells with glutamate (1 mmol/L) caused significant overactivation of GSK-3β and prevented β-catenin translocation to the nucleus. Pretreatment with carbachol (0.01 μmol/L) blocked glutamate-induced cell death and GSK-3β overactivation, and markedly enhanced β-catenin transcriptional activity.
CONCLUSION: Activation of muscarinic receptors exerts neuroprotection in PC12 cells by attenuating glutamate-induced GSK-3β overactivation, suggesting potential benefits of muscarinic agonists for Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685950      PMCID: PMC4002616          DOI: 10.1038/aps.2013.42

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  41 in total

Review 1.  Current approaches in the treatment of Alzheimer's disease.

Authors:  Reena S Shah; Hyoung-Gon Lee; Zhu Xiongwei; George Perry; Mark A Smith; Rudy J Castellani
Journal:  Biomed Pharmacother       Date:  2008-03-17       Impact factor: 6.529

Review 2.  Neuroprotective strategies in Alzheimer's disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  NeuroRx       Date:  2004-01

3.  Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta.

Authors:  M J Hart; R de los Santos; I N Albert; B Rubinfeld; P Polakis
Journal:  Curr Biol       Date:  1998-05-07       Impact factor: 10.834

4.  Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons.

Authors:  N Tong; J F Sanchez; S B Maggirwar; S H Ramirez; H Guo; S Dewhurst; H A Gelbard
Journal:  Eur J Neurosci       Date:  2001-05       Impact factor: 3.386

5.  HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity.

Authors:  S B Maggirwar; N Tong; S Ramirez; H A Gelbard; S Dewhurst
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

6.  Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal.

Authors:  M Hetman; J E Cavanaugh; D Kimelman; Z Xia
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

7.  Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons.

Authors:  O V Forlenza; J M Spink; R Dayanandan; B H Anderton; O F Olesen; S Lovestone
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

Review 8.  Cross-talk between oxidative stress and modifications of cholinergic and glutaminergic receptors in the pathogenesis of Alzheimer's disease.

Authors:  Zhi-zhong Guan
Journal:  Acta Pharmacol Sin       Date:  2008-07       Impact factor: 6.150

Review 9.  GSK-3: a key player in neurodegeneration and memory.

Authors:  Karl Peter Giese
Journal:  IUBMB Life       Date:  2009-05       Impact factor: 3.885

10.  A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

Authors:  L Serenó; M Coma; M Rodríguez; P Sánchez-Ferrer; M B Sánchez; I Gich; J M Agulló; M Pérez; J Avila; C Guardia-Laguarta; J Clarimón; A Lleó; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2009-06-10       Impact factor: 5.996

View more
  4 in total

1.  New monoamine antidepressant, hypidone hydrochloride (YL-0919), enhances the excitability of medial prefrontal cortex in mice via a neural disinhibition mechanism.

Authors:  Yong-Mei Zhang; Lu-Yu Ye; Tian-Yu Li; Fan Guo; Fei Guo; Yang Li; Yun-Feng Li
Journal:  Acta Pharmacol Sin       Date:  2021-11-22       Impact factor: 7.169

2.  Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma.

Authors:  Ping Yu; Wen-Pei Dong; Ya-Bin Tang; Hong-Zhuan Chen; Yong-Yao Cui; Xiao-Lan Bian
Journal:  Ann Transl Med       Date:  2021-02

Review 3.  Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.

Authors:  Mukesh K Pandey; Timothy R DeGrado
Journal:  Theranostics       Date:  2016-02-17       Impact factor: 11.556

4.  GSK-3β-Targeting Fisetin Promotes Melanogenesis in B16F10 Melanoma Cells and Zebrafish Larvae through β-Catenin Activation.

Authors:  Ilandarage Menu Neelaka Molagoda; Wisurumuni Arachchilage Hasitha Maduranga Karunarathne; Sang Rul Park; Yung Hyun Choi; Eui Kyun Park; Cheng-Yun Jin; Haiyang Yu; Wol Soon Jo; Kyoung Tae Lee; Gi-Young Kim
Journal:  Int J Mol Sci       Date:  2020-01-02       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.